Figure 4From: The therapeutic efficacy of I131-PSCA-mAb in orthotopic mouse models of prostate cancerThe SPECT for tumor-bearing nude mice at 1 h, 4 h, 8 h, 12 h and 24 h after intravenous injection of I131-PSCA-mAb. (a: tumor-bearing nude mice inoculated with androgen-independent PC-3 cells; b: tumor-bearing nude mice inoculated with androgen-dependent LNCaP cells).Back to article page